Komori
Governance4563AnGes,Inc.Pharmaceuticals

Corporate Governance Report 2026/03/30

The company is structured as a company with a board of corporate auditors. Its board of directors comprises 5 directors, including 3 outside directors, and its board of corporate auditors comprises 3 corporate auditors, all of whom are outside corporate auditors. No specific changes from the previous report are stated in the body of the report.

Worth reading
23Immaterial
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit & Supervisory Board
Number of directorsTotal: 5, including 3 outside directors
Committee1
Risk Management and Compliance Committee
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit & Supervisory Board
Number of directorsTotal: 5, including 3 outside directors
CommitteeRisk Management and Compliance Committee (proportion of outside members: Not disclosed)
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To describe the corporate governance framework and timely disclosure framework. No reason for the change is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/03/30 | AnGes,Inc. (4563) timely disclosure | Komori